Beyond weight loss, GLP-1s are currently approved for additional uses for people who have obesity, including Wegovy for cardiovascular risk reduction, Zepbound for sleep apnea, and Ozempic for slowing chronic kidney disease in people with Type 2 diabetes
The AcM enzyme used in this study is same as the one previously described [28] and marketed under the trade name of Balancius TM (dsm-firmenich animal nutrition and health, Wurmisweg, 576, 4303, Kaiseraugst, Switzerland).The gene coding for this AcM is from the fungus Acremonium alcalophilum (strain 114.92), and its activity is expressed in MUR units LSU(F)
47 KimuraH
They may prevent type 2 diabetes progression or even induce remission in early-stage cases
Jennifer Hardy Apr 20, 2025 8 min read The rapid rise of GLP-1 receptor agonists, such as semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound), has transformed the care of obesity and diabetes